
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is a promising company with potential treatments for inflammatory and autoimmune diseases, including the successful results of OD-001 in a Phase 2a ulcerative colitis trial and the expected entrance of OD-002 into clinical trials. The company's focus on targeting inflammatory pathways and potential for combination therapies further supports the positive outlook, but potential risks and setbacks should be considered. The expertise and leadership of Dr. Natalie Dales, Chief of Research Operations and Portfolio Strategy, adds to the company's potential for success.
Bears say
Odyssey Therapeutics is facing tough competition in the market and while they have promising data from previous trials, their current pipeline is still in the clinical stage. The estimated high gross margin of 95% and potential FDA approval may seem positive, but as a financial analyst the focus is on potential future revenue and profits which may take a significant amount of time to materialize. Furthermore, the company's reliance on one physician-scientist for their expertise and patents could pose a risk in case of any unexpected events.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares